In addition, the BU researchers have developed a new computational strategy to analyze this data and specifically identify key biological pathways (molecular circuits) that are active in cancer and "dormant" in normal cells. The study which appears in the November 25th issue of PLoS ONE, will ultimately lead to the development of drugs specifically aimed to inhibit these proteins.
According to the BU researchers, there are many features that make cancer cells different from normal cells. They look different histologically, they proliferate and divide at different rates, they are immortal unlike normal cells, and are less communicative with their neighbor cells. They are also more "selfish" in refusing to commit suicide (programmed cell death) which normal cells do when their genomes become unstable.
Much of the cellular machinery involved with these biological processes is controlled by a command control and communication system called signal transduction. Signal transduction is in large part controlled by a process called phosphorylation. When a protein is phosphorylated it either becomes active or repressed depending on its special function. "Therefore, identifying the phosphorylation status of proteins in cancer cells versus normal cells provides us with a unique ability to understand and perhaps intervene with the command and control center of cancer cells," said co-senior author Simon Kasif, PhD, who is the co-director of the Center of Advanced Genomic Technology and a professor in the department of biomedical engineering at BU. "Drugs are most effective on cancers when they attack the proteins that are activated," he added.
While cancers are highly heterogeous in their make-up, the BU researchers believe that a drug that would target this collection of proteins would be effective treatment for most lung cancers.
"This is the first statistically validated phosphopeptide signature to diagnose any disease, much less cancer or lung cancer," explained senior co-author Martin Steffen, MD, PhD, an assistant professor of pathology and laboratory medicine at BUSM, and director, Proteomics Core Facility at BUSM.
This research was performed in collaboration with Cell Signaling Technology employing their Phosphoscan "test kit".
A follow-up study is currently underway at BU to identify which cancers respond or not respond to existing cancer drugs based on the results of this test.
Funding for this study was provided by the National Human Genome Research Institute and the American Lung Association.
Gina DiGravio | EurekAlert!
On track to heal leukaemia
18.01.2017 | Universitätsspital Bern
Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).
Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...
10.01.2017 | Event News
09.01.2017 | Event News
05.01.2017 | Event News
18.01.2017 | Power and Electrical Engineering
18.01.2017 | Materials Sciences
18.01.2017 | Life Sciences